Experimental drug aims to boost CAR-T power against lymphoma
NCT ID NCT07361224
First seen Jan 23, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This early-stage trial tests whether adding a drug called CLS-015 to standard CAR-T cell therapy can help people with large B-cell lymphoma whose disease is stable or getting worse. CLS-015 works by breaking down NETs, which are immune-trapping webs that may block CAR-T cells. The study will enroll 12 adults and focus on safety, not yet on cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sourasky Medical Center
RECRUITINGTel Aviv, 6423906, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLS-015 (a drug that breaks down NETs) given alongside CAR-T cell therapy
What this could lead to
If it works, this could improve how well CAR-T therapy fights large B-cell lymphoma, especially in patients whose disease is stable or progressing.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so safety and effectiveness are not yet proven. The added drug may cause side effects or not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.